US Patent

US9993466 — Donepezil transdermal delivery system

Formulation · Assigned to Corium International Inc · Expires 2037-07-26 · 11y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a transdermal delivery system for donepezil hydrochloride that allows for systemic delivery of the drug through the skin.

USPTO Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Drugs covered by this patent

Patent Metadata

Patent number
US9993466
Jurisdiction
US
Classification
Formulation
Expires
2037-07-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Corium International Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.